## Organ Transplantation: The Technologies and Ethics of Replacing What Fails

Every year, hundreds of thousands of people around the world wait for an organ that may never come. In 2024, over 668,000 patients were on transplant waiting lists globally, and nearly 32,000 died waiting. The gap between what human bodies need and what medicine can supply has driven some of the most consequential — and morally fraught — technologies in modern history. And the question of how we close that gap reveals as much about our values as about our science.

### What Is Organ Transplantation?

Organ transplantation is the replacement of a failing organ with a functioning one — from a living donor, a deceased donor, or increasingly from engineered or animal sources. Since the first successful kidney transplant in 1954, the field has expanded to include hearts, livers, lungs, pancreases, and more. It is one of medicine's great achievements, turning what was once a death sentence into a manageable condition.

But the achievement has always been constrained by supply. Demand for organs far exceeds the number of donors, and the shortfall has created a cascade of consequences: years-long waiting lists, agonizing triage decisions, a black market that the WHO estimates accounts for 5–10 percent of all transplants worldwide, and a persistent search for alternatives — from xenotransplantation (using organs from genetically modified animals) to bioprinting (manufacturing organs from a patient's own cells). Each alternative brings its own technical challenges and ethical questions, and the history of organ replacement is a history of societies deciding what they are willing to accept in order to save lives.

### How the Book Explores It

*Films from the Future* approaches organ transplantation from two directions. Chapter 3, through the film *Never Let Me Go*, presents the darkest possible version: a society that has solved the organ shortage by cloning human beings and harvesting their organs. The clones are raised with care — even love — yet they are never granted the basic rights afforded to other people. Society has convinced itself that they are somehow less than human, a convenient lie that allows the program to continue.

The chapter identifies a framework the book calls "too valuable to fail": once a society becomes dependent on a technology, even one with deeply troubling ethical dimensions, the pressure to maintain it can overwhelm moral objections. The organ donation program in *Never Let Me Go* cannot be dismantled because too many lives, too much infrastructure, too much comfort depends on it continuing. As the book observes, technology has the power to rob us of our souls, even as it sustains our bodies — not because it changes who we are, but because it makes us forget the worth of others.

Chapter 6, through *Elysium*, presents the aspirational counterpart: medical pods that can reconstruct human tissue and bone in seconds. The real-world technology behind this — bioprinting — offers the prospect of organs manufactured on demand from a patient's own cells, eliminating both the donor shortage and the risk of rejection. But in *Elysium*, this technology is available only to the wealthy residents of an orbiting space station, while the people on Earth are left with outdated medicine and preventable death. The question shifts: even if we solve the supply problem, who gets access?

### Where Things Stand Today

The organ transplant landscape has changed dramatically since the book was published. In 2024, a record 173,727 solid organ transplants were performed worldwide — yet this meets only an estimated 10 percent of global demand, with enormous disparities between countries.

The most striking development is xenotransplantation. In March 2024, Massachusetts General Hospital performed the world's first transplant of a genetically edited pig kidney into a living human recipient. By early 2025, the US Food and Drug Administration had approved the first clinical trial of pig-to-human kidney transplants, moving the field from individual compassionate-use cases to a systematic programme. The pig kidneys are edited using CRISPR to remove harmful pig genes and add human genes that improve compatibility — a convergence of genetic engineering, immunology, and surgical technique that would have seemed speculative a decade ago.

Bioprinting has also advanced, though more slowly. Researchers have bioprinted skin patches, cartilage, blood vessels, and liver tissue that can metabolize drugs in the laboratory. But printing a fully functional organ — with its intricate network of blood vessels, nerves, and multiple cell types — remains a formidable challenge. As of 2025, only eleven qualifying clinical bioprinting trials had been registered globally, revealing how early the field remains in clinical translation.

### Why It Matters

Organ transplantation sits at the intersection of nearly every ethical framework the book develops. It raises questions about human dignity — what does it mean to treat a living being as a source of spare parts? About power, privilege, and access — who gets a transplant when there are not enough to go around? About the technologies we become dependent on — and the moral compromises we accept to keep them running?

The book's treatment of *Never Let Me Go* makes a broader point: the way a society manages its organ supply reveals what it is willing to tolerate. The clones in the film are not hidden. Everyone knows. The moral failure is not ignorance but indifference — the collective decision that the benefits are worth the cost, as long as the cost is borne by someone else. This is, as the book argues, a pattern that recurs whenever powerful technologies are deployed without asking who is harmed.

As xenotransplantation moves from experiment to clinic, and as bioprinting inches toward functional organs, the supply problem may eventually be solved. But the ethical questions will not disappear with it. They will shift: from who gets access to donor organs, to who gets access to engineered ones. The technology changes. The underlying question — what we owe each other when life is on the line — does not.

### Explore Further

- [Cloning and Reproductive Biology](https://spoileralert.wtf/md-files/est_cloning.md) — creating biological sources for organs, and the ethical boundaries of doing so
- [Bioprinting and Organ Regeneration](https://spoileralert.wtf/md-files/est_bioprinting.md) — manufacturing replacement organs from a patient's own cells
- [Genetic Engineering and Gene Editing](https://spoileralert.wtf/md-files/est_genetic_engineering.md) — the tools that make xenotransplantation and engineered organs possible
- [Human Dignity and What Makes Us Human](https://spoileralert.wtf/md-files/rei_human_dignity.md) — what organ harvesting reveals about how we value life
- [Too Valuable to Fail](https://spoileralert.wtf/md-files/rei_too_valuable_to_fail.md) — when organ supply systems become too entrenched to challenge

## Further Reading

- [Organ Donation and Transplantation Worldwide: The Global Observatory on Donation and Transplantation 2024 Report — PMC/NIH, 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12908642/) — The most comprehensive global data on organ transplantation, covering 92 countries. Reports a record 173,727 transplants in 2024 while documenting the persistent shortfall: 668,160 patients on waiting lists and 31,853 deaths while waiting.

- [World-first pig kidney trials mark turning point for xenotransplantation — *Nature*, 2025](https://www.nature.com/articles/d41591-025-00020-0) — Reports on the FDA's approval of the first clinical trials for pig-to-human kidney transplants, marking the transition of xenotransplantation from individual compassionate-use cases to a systematic research programme. A pivotal moment for the field.

- [First Gene-Edited Pig Kidney Transplant Clinical Trial Begins at NYU Langone Health — NYU Langone, 2025](https://nyulangone.org/news/first-gene-edited-pig-kidney-transplant-clinical-trial-begins-nyu-langone-health) — Details the launch of the first FDA-approved trial, including the CRISPR-based gene editing techniques used to improve compatibility between pig organs and human immune systems.

- [Recent progress in pig-to-human kidney xenotransplantation — *Frontiers in Immunology*, 2025](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1735113/full) — A comprehensive review of the science underlying xenotransplantation, including the immunological challenges that remain even after gene editing. Directly relevant to the book's frameworks around unintended consequences in complex biological systems.

- [Global transplantation: Lessons from organ donation — PMC/NIH, 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11612884/) — Examines policy approaches to increasing organ donation rates worldwide, including the Spanish model that has achieved the highest donation rates in the world. Connects to the book's emphasis on governance, equity, and the social dimensions of technological solutions.

- [The Global Organ Crisis: Human Trafficking and the Illicit Organ Trade — *Public Safety Magazine*, 2025](https://publicsafetymagazine.com/global-organ-crisis/) — Documents the human cost of the organ shortage: the WHO estimates that 5–10 percent of all transplants worldwide involve organs obtained through trafficking. A stark real-world parallel to the exploitation the book identifies in *Never Let Me Go*.

- [Q&A with author Andrew Maynard on Films from the Future — Future of Being Human](https://www.futureofbeinghuman.com/p/everything-you-wanted-to-know-about-films-from-the-future-but-were-afraid-to-ask-f75b11efec13) — Andrew Maynard's own discussion of the book's themes, including his approach to the ethical questions raised by technologies that sustain life at a cost that is borne unevenly.